Nifluridide, an experimental insecticide, is used for the control of sucking and biting insects such as Phthiraptera. Nifluridide was systemically active against Triatoma infestans on mice and Rhodnius prolixus on cattle.

Pamaqueside, an 11-ketotigogenin cellobioside was developed as a cholesterol absorption inhibitor for the treatment of hypercholesterolemia. This drug participated in phase III clinical trial; however, information about the further development of this drug is not available.

Lubeluzole is a medication, developed by Janssen Research Foundation for the treatment of acute ischemic stroke. The drug action is discussed to involve the inhibition of NMDA receptor and sodium channels.

Primycin is a topical antibiotic developed in Hungary for the local treatment of certain superficial and deep infections of the skin and subcutaneous tissue. Primycin is a complex of macrocyclic antibiotics comprising 20 compounds. Primycin possesses good in vitro activity against Staphylococcus aureus and coagulase-negative staphylococci, but its activity against Sirepiococctts pyogenes and enterococci is moderate. It is active against Micrococcus and Bacillus spp. but is inactive against Corynebacterium spp. It is inactive against Enterofojcterwceae and Pseudomonas aeruginosa, yeasts, and dermatophytes. The median lethal dose in the mouse is greater than 3,000 mg/kg of body weight orally and 56 mg/kg intraperitoneally. No skin lesions have been observed after chronic cutaneous applications (90 days) in the rabbit.

Fluprazine (previously known as DU27716), a psychoactive drug was studied as a behaviorally selective, anti-aggressive agent. Experiments on rodents have shown that fluprazine didn’t appreciably affect defensive attack or other defensive behaviors even though it strongly inhibited offensive attack. This agent is used to test both differences and similarities in neurochemical substrates and adaptive significance of different forms of intraspecific aggression.

Enciprazine also known as WY-48624 or, D-3112 is a GABA A receptor agonist which was in the phase III of clinical trial for the treatment of anxiety disorders. Enciprazine was well tolerated, with low levels of sedative and asthenic side effects reported. However, research was discontinued.

Thymocartin (also known as T4 and RGH-0206) is a protected synthetic tetrapeptide patented by Hungarian multinational pharmaceutical and biotechnology company Gedeon Richter Plc. (Richter, Gedeon, Vegyeszeti Gyar Rt) as an immunomodulating agent. In preclinical models, Thymocartin shows to exert similar immunomodulatory activities to thymopoietin affecting both humoral and cellular responses. In skin graft mouse model Thymocartin increases the number of splenic T cells and restored the rejection capacity of thymectomized C57Bl mice. In chronic 28-days i.v. toxicity studies in dogs no adverse reaction has been found. The low toxicity of Thymocartin is probably attributable to their short half-life as the half-life of the Thymocartin is less than 3 min in humans.

Tiqueside is the synthetic spirostane-based steroid glycoside. It precipitates cholesterol from micellar solution in vitro and reduces plasma cholesterol absorption in rats through a mechanism that is currently thought to be independent of either association of the saponin with the intestinal mucosal surface or absorption of the saponin molecule. As a consequence of this inhibition, tiqueside has been shown to reduce plasma cholesterol concentrations in cynomolgus monkeys. Inhibition of cholesterol absorption by tiqueside produces profound effects on cholesterol metabolism without affecting bile acid metabolism, and these changes lead to reductions primarily in plasma non-HDL cholesterol concentrations. Tiqueside produced a dose-dependent reduction in plasma LDL cholesterol levels in the hypercholesterolemic patients. In the mechanistic study, it decreased fractional cholesterol absorption rates and increased fecal neutral sterol excretion rates, changes associated with trends toward lower LDL cholesterol levels. Other lipoprotein levels were unaffected, as were fecal fat and bile acid excretion and fat-soluble vitamin absorption. Thus tiquesidedose-dependently inhibits cholesterol absorption in humans, resulting in a reduction in serum LDL cholesterol levels.

Furostilbestrol (diethylstilbestrol di(2-furoate)) is a synthetic estrogen that was first described in 1952. It is an ester of diethylstilbestrol (DES), a synthetic estrogen that was prescribed to pregnant women until 1971 to prevent miscarriages and that has been associated with cancer, birth defects and several other developmental abnormalities. Furostilbestrol was never marketed.